Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 20;11(1):3637.
doi: 10.1038/s41467-020-17380-5.

Magnetic field boosted ferroptosis-like cell death and responsive MRI using hybrid vesicles for cancer immunotherapy

Bo Yu  1 , Bongseo Choi  1 , Weiguo Li  1   2 , Dong-Hyun Kim  3   4   5   6
Affiliations

Magnetic field boosted ferroptosis-like cell death and responsive MRI using hybrid vesicles for cancer immunotherapy

Bo Yu et al. Nat Commun. .

Abstract

We report a strategy to boost Fenton reaction triggered by an exogenous circularly polarized magnetic field (MF) to enhance ferroptosis-like cell-death mediated immune response, as well as endow a responsive MRI capability by using a hybrid core-shell vesicles (HCSVs). HCSVs are prepared by loading ascorbic acid (AA) in the core and poly(lactic-co-glycolic acid) shell incorporating iron oxide nanocubes (IONCs). MF triggers the release of AA, resulting in the increase of ferrous ions through the redox reaction between AA and IONCs. A significant tumor suppression is achieved by Fenton reaction-mediated ferroptosis-like cell-death. The oxidative stress induced by the Fenton reaction leads to the exposure of calreticulin on tumor cells, which leads to dendritic cells maturation and the infiltration of cytotoxic T lymphocytes in tumor. Furthermore, the depletion of ferric ions during treatment enables monitoring of the Fe reaction in MRI-R2* signal change. This strategy provides a perspective on ferroptosis-based immunotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Exogenous MF-boosted Ferroptosis-like cell death.
a Scheme of exogenous MF-boosted Fenton reaction and responsive magnetic resonance imaging (MRI) using HCSVs, b TEM images of HCSVs treated with the circularly polarized magnetic field (MF, 2 Hz) for various time-periods. Experiments were repeated three times. c Relative concentration change of Ferrous ions tested by the ferrous probe, n = 3 independent samples. Data are shown as means ± s.d. d Ferrostatin-1 rescued TRAMP-C1 cells treated with HCSVs with/without MF, n = 3 independent samples. P = 0.017 e Flow cytometry assay of calreticulin (CRT) exposure on the surface of TRAMP-C1 after various treatment. f Relative quantification of Flow cytometry assay of CRT exposure. n = 3 independent samples. Data are shown as means ± s.d. p < 0.05, two-tailed paired t-test. Source data are provided as a Source data file.
Fig. 2
Fig. 2. Responsive MRI.
a In vitro R2* value of IONCs treated with/without AA, R square are 0.9963 and 0.8287 for IONCs (black cure) and IONCs + AA (red curve), respectively. b In vivo R2* change after intra-tumoral injection of HCSVs treated with/without MF. R square are 0.9520 and 0.9741 for red curve (with MF) and blue curve (without MF), respectively. (n = 3 independent samples) Data are shown as means ± s.d. c Related R2* mapping after intra-tumoral injection of HCSVs treated with/without MF (red cycle indicated tumor region). Source data are provided as a Source data file.
Fig. 3
Fig. 3. Combination therapy-mediated antitumor effect in a TRAMP-C1 tumor model.
a in vivo treatment timeline. b tumor growth curves of the TRAMP-C1. c the record of mouse weight. d tumor weight at the end time point. (n = 6 independent samples). Data are shown as means ± s.d. e the typical ex vivo photo of dissected tumors from various treatment. (n = 6 independent samples) f TUNEL-stained tumor slices (scale bar: 2.5 mm). Tumor tissues collected from different groups at 24 h after various treatments. Experiments were performed one time. Source data are provided as a Source data file.
Fig. 4
Fig. 4. Immune responses after treatment to TRAMP-C1 tumor-bearing mice.
Flow cytometric analysis images (a) and the statistical data (b) for in vivo DC maturation. Cells in the tumor-draining lymph nodes were collected after various treatments for the assessment by flow cytometry after staining with CD11c, CD80, and CD86. **p = 0.0044. Representative flow cytometric analysis images showing CD8+ T cells (CD3+ CD4- CD8+) from different groups of mice. Proportions of tumor infiltrating CD8+ killer T cells in the tumor (up line) and draining lymph nodes (down line) (c) and the statistical data in the tumor (d) (**p = 0.0013) and in lymph node (e) among all cancer cells (*p = 0.0491) (n = 6 independent samples). The percentage values in the graphs were defined in relation to T cell populations. Data are shown as means ± s.d. two-tailed paired t-test. Source data are provided as a Source data file.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hu QY, Sun WJ, Wang C, Gu Z. Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv. Drug Deliv. Rev. 2016;98:19–34. doi: 10.1016/j.addr.2015.10.022. - DOI - PMC - PubMed
    1. Zhou F, et al. Tumor microenvironment-activatable prodrug vesicles for nanoenabled cancer chemoimmunotherapy combining immunogenic cell death induction and CD47 blockade. Adv. Mater. 2019;31:e1805888. doi: 10.1002/adma.201805888. - DOI - PubMed
    1. Feng B, et al. Binary cooperative prodrug nanoparticles improve immunotherapy by synergistically modulating immune tumor microenvironment. Adv. Mater. 2018;30:e1803001. doi: 10.1002/adma.201803001. - DOI - PubMed
    1. Chen Q, et al. Nanoparticle-enhanced radiotherapy to trigger robust cancer immunotherapy. Adv. Mater. 2019;31:e1802228. doi: 10.1002/adma.201802228. - DOI - PubMed
    1. Ng CP, Bonavida B. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. Adv. Cancer Res. 2002;85:145–174. doi: 10.1016/S0065-230X(02)85005-9. - DOI - PubMed

Publication types

MeSH terms

  NODES
twitter 2